Imagine if a new multicenter, randomized trial of a pharmaceutical drug found that for every
3 patients treated on presentation to the hospital with a common severe illness, one
intubation and an intensive care unit (ICU) admission were prevented. This would be an
instant blockbuster drug. Insurers would scramble to reimburse it, and guidelines and quality
metrics would be established to facilitate implementation. In the setting of worsening hospital
and ICU strain globally, health systems would work rapidly to implement pathways for using …